Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Tough times continue for stem cell patents
Biotechnology
The exclusion from patentability of certain cells derived from human embryos is a reflection of the EPO’s increasingly restrictive stance, say Franz-Josef Zimmer and Markus Grammel.   20 June 2014
The post-Medeva SPC saga: what about biologicals?
Biotechnology
For those involved in the development of biological drugs, the prospects of getting what would seem to be a ‘fair reward’ may not have improved much, says Jaap Mannaerts.   20 June 2014
Indian patent law: a new direction
Asia
Recent decisions suggest that the Indian system seems to be changing direction towards developing sound patent law jurisprudence, says Archana Shanker.   20 June 2014
Americas
The rate of development in the biotech sector means revisions to the patent guidelines are more needed than ever, says Marisa Moura Momoli.   20 June 2014
Asia-Pacific
China, Japan and South Korea are three of the most developed markets in the world for pharmaceuticals but they still offer a wealth of opportunities for both innovators and generic drug companies. LSIPR looks at the protection available for those seeking to do business there.   20 June 2014
Asia-Pacific
Amendments to SIPO’s guidelines for the examination of utility patents may help stop the proliferation of ‘junk’ utility models in China. Wolfgang Bublak and Yingkun Brunner report.   20 June 2014
Genetics
The realm of patent eligibility under 35 USC §101 has become more confusing, with the introduction of a possible new definition of admissibility after a decision on Dolly the sheep. Nabeela Rasheed reports.   20 June 2014
Big Pharma
Andrew Wright and Tom Harding investigate how a decision by the EPO’s Board of Appeal may extend the opportunities for protection by second medical use claims.   20 June 2014
Americas
Acting against infringers can involve the pharmaceutical regulatory framework and civil law as well as following the more usual pathways, says José R. Trigueros.   20 June 2014
Generics
There is no uniform interpretation of the scope of the Bolar exemption in Europe, but a CJEU opinion harmonising the issue may be on the way, says Rafal Witek.   20 June 2014